日本のインスリンドラッグデリバリー市場レポート：タイプ別、地域別、2025年～2033年

日本のインスリンドラッグデリバリーの市場規模は2024年に20億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに39億米ドルに達し、2025年から2033年にかけて6.75%の成長率（CAGR）を示すと予測しています。日本における糖尿病罹患率の増加と、新しいインスリン製剤や特殊なデリバリーデバイスを必要とする薬剤の開発が、主に市場を牽引しています。

本レポートで扱う主な質問

• 日本のインスリンドラッグデリバリー市場はこれまでどのように推移してきたか？
• COVID-19が日本のインスリンドラッグデリバリー市場に与えた影響は？
• 日本のインスリンドラッグデリバリー市場のタイプ別区分は？
• 日本のインスリンドラッグデリバリー市場のバリューチェーンにおける様々な段階とは？
• 日本のインスリンドラッグデリバリーの主な促進要因と課題は？
• 日本のインスリンドラッグデリバリー市場の構造と主要プレーヤーは？
• 日本のインスリンドラッグデリバリー市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
• 市場推定
• 調査手法

第3章 エグゼクティブサマリー

第4章 日本のインスリンドラッグデリバリー市場：イントロダクション

• 概要
• 市場力学
• 業界動向
• 競合情報

第5章 日本のインスリンドラッグデリバリー市場情勢

• 過去および現在の市場動向（2019～2024年）
• 市場予測（2025～2033年）

第6章 日本のインスリンドラッグデリバリー市場：タイプ別内訳

• 薬剤
• デバイス

第7章 日本のインスリンドラッグデリバリー市場：競合情勢

• 概要
• 市場構造
• 市場企業のポジショニング
• 主要成功戦略
• 競合ダッシュボード
• 企業評価象限

第8章 主要企業のプロファイル

第9章 日本のインスリンドラッグデリバリー市場：業界分析

• 促進要因、抑制要因、機会
• ポーターのファイブフォース分析
• バリューチェーン分析

第10章 付録

Japan insulin drugs delivery devices market size reached USD 2.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.75% during 2025-2033. The increasing incidences of diabetes in Japan coupled with the development of new insulin formulations and drugs that require specialized delivery devices are primarily driving the market.

Insulin drugs delivery devices are essential tools for individuals suffering from diabetes, a chronic condition characterized by impaired insulin production or utilization. These devices enable precise and convenient administration of insulin, a hormone crucial for regulating blood sugar levels. One of the most notable advancements in insulin delivery is the insulin pen, which resembles a regular pen and allows for accurate dosing with a simple push of a button. Its discreet design and portability have made it a popular choice for type 1 and type 2 diabetics. Additionally, insulin pumps offer continuous subcutaneous insulin infusion, mimicking the natural insulin release in the body. These devices provide precise control over insulin dosage and can be programmed to match an individual's unique needs. Furthermore, the development of smart insulin delivery systems, which integrate with mobile apps and continuous glucose monitors, has further improved diabetes management. These devices enable real-time tracking of blood sugar levels and automated insulin adjustments, reducing the burden of constant monitoring and decision-making for patients.

Japan Insulin Drugs Delivery Devices Market Trends:

The insulin drugs delivery devices market in Japan is poised for significant growth, primarily due to several compelling drivers. Firstly, the rising prevalence of diabetes is a pivotal factor propelling market expansion. Moreover, the increasing awareness about diabetes management and the importance of timely insulin administration among patients and healthcare providers is contributing to the market's upward trajectory. Additionally, technological advancements in insulin delivery devices, such as the development of smart insulin pens and wearable insulin pumps, are driving patient convenience and adherence. Furthermore, the growing geriatric population, who are more susceptible to diabetes, is augmenting the demand for these devices. Apart from this, the escalating obesity rates and sedentary lifestyles in Japan are fueling the incidence of type 2 diabetes, further bolstering the insulin drugs delivery devices market. Additionally, the pursuit of personalized medicine and tailored insulin therapies is fostering innovation in device design and functionality. Moreover, favorable reimbursement policies for diabetes management products, which incentivize patients to adopt advanced insulin drugs delivery devices, are expected to drive the market in Japan during the forecast period.

Japan Insulin Drugs Delivery Devices Market Segmentation:

Type Insights:

• Drug
  • Basal or Long-Acting Insulins
• Lantus (Insulin Glargine)
• Levemir (Insulin Detemir)
• Toujeo (Insulin Glargine)
• Tresiba (Insulin Degludec)
• Basaglar (Insulin Glargine)
  • Bolus or Fast-Acting Insulins
• NovoRapid/Novolog (Insulin aspart)
• Humalog (Insulin lispro)
• Apidra (Insulin glulisine)
• FIASP (Insulin aspart)
• Admelog (Insulin lispro Sanofi)
  • Traditional Human Insulins
• Novolin/Mixtard/Actrapid/Insulatard
• Humulin
• Insuman
  • Combination Insulins
• NovoMix (Biphasic Insulin aspart)
• Ryzodeg (Insulin degludec and Insulin aspart)
• Xultophy (Insulin degludec and Liraglutide)
• Soliqua/Suliqua (Insulin glargine and Lixisenatide)
  • Biosimilar Insulins
• Insulin Glargine Biosimilars
• Human Insulin Biosimilars
• Device
  • Insulin Pumps
• Insulin Pump Devices
• Insulin Pump Reservoirs
• Insulin Infusion sets
  • Insulin Pens
• Cartridges in reusable pens
• Disposable insulin pens
  • Insulin Syringes
  • Insulin Jet Injectors

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan insulin drugs delivery devices market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan insulin drugs delivery devices market?
• What is the breakup of the Japan insulin drugs delivery devices market on the basis of type?
• What are the various stages in the value chain of the Japan insulin drugs delivery devices market?
• What are the key driving factors and challenges in the Japan insulin drugs delivery devices?
• What is the structure of the Japan insulin drugs delivery devices market and who are the key players?
• What is the degree of competition in the Japan insulin drugs delivery devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Insulin Drugs Delivery Devices Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Insulin Drugs Delivery Devices Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Insulin Drugs Delivery Devices Market - Breakup by Type

• 6.1 Drug
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Segmentation
    • 6.1.3.1 Basal or Long-Acting Insulins
      • 6.1.3.1.1 Lantus (Insulin Glargine)
      • 6.1.3.1.2 Levemir (Insulin Detemir)
      • 6.1.3.1.3 Toujeo (Insulin Glargine)
      • 6.1.3.1.4 Tresiba (Insulin Degludec)
      • 6.1.3.1.5 Basaglar (Insulin Glargine)
    • 6.1.3.2 Bolus or Fast-Acting Insulins
      • 6.1.3.2.1 NovoRapid/Novolog (Insulin Aspart)
      • 6.1.3.2.2 Humalog (Insulin lispro)
      • 6.1.3.2.3 Apidra (Insulin Glulisine)
      • 6.1.3.2.4 FIASP (Insulin Aspart)
      • 6.1.3.2.5 Admelog (Insulin lispro Sanofi)
    • 6.1.3.3 Traditional Human Insulins
      • 6.1.3.3.1 Novolin/Mixtard/Actrapid/Insulatard
      • 6.1.3.3.2 Humulin
      • 6.1.3.3.3 Insuman
    • 6.1.3.4 Combination Insulins
      • 6.1.3.4.1 NovoMix (Biphasic Insulin aspart)
      • 6.1.3.4.2 Ryzodeg (Insulin Degludec and Insulin aspart)
      • 6.1.3.4.3 Xultophy (Insulin Degludec and Liraglutide)
      • 6.1.3.4.4 Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
    • 6.1.3.5 Biosimilar Insulins
      • 6.1.3.5.1 Insulin Glargine Biosimilars
      • 6.1.3.5.2 Human Insulin Biosimilars
  • 6.1.4 Market Forecast (2025-2033)
• 6.2 Device
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Segmentation
    • 6.2.3.1 Insulin Pumps
      • 6.2.3.1.1 Insulin Pump Devices
      • 6.2.3.1.2 Insulin Pump Reservoirs
      • 6.2.3.1.3 Insulin Infusion Sets
    • 6.2.3.2 Insulin Pens
      • 6.2.3.2.1 Cartridges in Reusable Pens
      • 6.2.3.2.2 Disposable Insulin Pens
    • 6.2.3.3 Insulin Syringes
    • 6.2.3.4 Insulin Jet Injectors
  • 6.2.4 Market Forecast (2025-2033)

7 Japan Insulin Drugs Delivery Devices Market - Competitive Landscape

• 7.1 Overview
• 7.2 Market Structure
• 7.3 Market Player Positioning
• 7.4 Top Winning Strategies
• 7.5 Competitive Dashboard
• 7.6 Company Evaluation Quadrant

8 Profiles of Key Players

• 8.1 Company A
  • 8.1.1 Business Overview
  • 8.1.2 Product Portfolio
  • 8.1.3 Business Strategies
  • 8.1.4 SWOT Analysis
  • 8.1.5 Major News and Events
• 8.2 Company B
  • 8.2.1 Business Overview
  • 8.2.2 Product Portfolio
  • 8.2.3 Business Strategies
  • 8.2.4 SWOT Analysis
  • 8.2.5 Major News and Events
• 8.3 Company C
  • 8.3.1 Business Overview
  • 8.3.2 Product Portfolio
  • 8.3.3 Business Strategies
  • 8.3.4 SWOT Analysis
  • 8.3.5 Major News and Events
• 8.4 Company D
  • 8.4.1 Business Overview
  • 8.4.2 Product Portfolio
  • 8.4.3 Business Strategies
  • 8.4.4 SWOT Analysis
  • 8.4.5 Major News and Events
• 8.5 Company E
  • 8.5.1 Business Overview
  • 8.5.2 Product Portfolio
  • 8.5.3 Business Strategies
  • 8.5.4 SWOT Analysis
  • 8.5.5 Major News and Events

9 Japan Insulin Drugs Delivery Devices Market - Industry Analysis

• 9.1 Drivers, Restraints and Opportunities
  • 9.1.1 Overview
  • 9.1.2 Drivers
  • 9.1.3 Restraints
  • 9.1.4 Opportunities
• 9.2 Porters Five Forces Analysis
  • 9.2.1 Overview
  • 9.2.2 Bargaining Power of Buyers
  • 9.2.3 Bargaining Power of Suppliers
  • 9.2.4 Degree of Competition
  • 9.2.5 Threat of New Entrants
  • 9.2.6 Threat of Substitutes
• 9.3 Value Chain Analysis

10 Appendix